Textilinin‐1, an alternative anti‐bleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss

@article{Flight2009Textilinin1AA,
  title={Textilinin‐1, an alternative anti‐bleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss},
  author={S. Flight and L. Johnson and Q. Du and R. Warner and M. Trabi and P. Gaffney and M. Lavin and J. de Jersey and P. Masci},
  journal={British Journal of Haematology},
  year={2009},
  volume={145}
}
Aprotinin has been used widely in surgery as an anti‐bleeding agent but is associated with a number of side effects. We report that textilinin‐1, a serine protease inhibitor from Pseudonaja textilis venom with sequence relatedness to aprotinin, is a potent but reversible plasmin inhibitor and has a narrower range of protease inhibition compared to aprotinin. Like aprotinin, textilinin‐1 at 5 μmol/l gave almost complete inhibition of tissue plasminogen activator‐induced fibrinolysis of whole… Expand
Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis‐Related Disorders
TLDR
Functional and structural aspects of plasmin inhibitors are highlighted with the goal of advancing their design for resolving other disease states including cell metastasis, cell proliferation, angiogenesis, and embryo implantation. Expand
Antifibrinolytic Role of a Bee Venom Serine Protease Inhibitor That Acts as a Plasmin Inhibitor
TLDR
A novel mechanism by which bumblebee venom affects the hemostatic system through the antifibrinolytic activity of Bi-KTI and through Bi-VSP-mediated fibrin(ogen)olytic activities is demonstrated, raising interest in Bi- KTI and Bi- VSP as potential clinical agents. Expand
Targeting anticoagulant protein S to improve hemostasis in hemophilia.
TLDR
The results establish PS inhibition as both controller of coagulation and potential therapeutic target in hemophilia as well as the murine PS silencing RNA approach that was successfully used in Hemophilic mice to protect them against bleeding. Expand
Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1
TLDR
KD1-Y11T/L17R-KCOOH is comparable to aprotinin, the most potent known inhibitor of plasmin and can be produced in large amounts using Pichia, as well as other antifibrinolytic agents. Expand
Structural studies of plasmin inhibition.
TLDR
The rationale for the further development of new Plm inhibitors is reviewed, with a particular focus on the structural studies of the active site inhibitors of Plm. Expand
The structure of Human Microplasmin in Complex with Textilinin-1, an Aprotinin-like Inhibitor from the Australian Brown Snake
TLDR
The unusual mode of interaction between textil inin-1 and plasmin explains textilin in-1′s selectivity for human plasmine over plasma kallikrein and can be exploited in future drug design efforts. Expand
Functional characterization of a slow and tight-binding inhibitor of plasmin isolated from Russell's viper venom.
TLDR
The first in-depth functional characterization of a plasmin inhibitor from a viperid snake is presented, which makes it a potential candidate for the development of novel antifibrinolytic agents. Expand
Antifibrinolytic Therapy and Perioperative Considerations.
TLDR
The role of fibrinolysis as a pathologic mechanism is explored, the different pharmacologic agents used to inhibit fibrinelysis are reviewed, and the role of tranexamic acid as a therapeutic agent to reduce bleeding in patients after surgery and trauma is focused on. Expand
The study on the inhibitory effect of rPI-T1 on kallikrein
TLDR
To comparatively study the effects of rPI-T1 with aprotinin and tranexamic acid, antifibrinolytic hemostatics currently used in clinical settings, by comparatively analyzing their inhibitory activities on plasmin, trypsin and kallikrein, the potential side effects resulting from inhibiting kallIKrein can be avoided. Expand
Natural and Engineered Plasmin Inhibitors: Applications and Design Strategies
TLDR
There is a need for further development of high‐affinity plasmin inhibitors that maintain selectivity over other serine proteases, and design strategies to obtain the potency and specificity of inhibition in addition to controlled temporal and spatial distribution tailored for the intended use. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Comparison of Textilinin-1 with Aprotinin as Serine Protease Inhibitors and as Antifibrinolytic Agents
TLDR
From data, textilinin-1 appears to be a more specific plasmin inhibitor than aprotinin but aProtinin inhibits clot lysis to a greater extent. Expand
Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model
  • P. Masci, A. Whitaker, +5 authors P. Gaffney
  • Medicine
  • Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • 2000
TLDR
It is proposed that the kinetic profiles of Txln 1 and 2 for plasmin allow the arrest of haemorrhage without the possible threat of thrombosis. Expand
Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro.
TLDR
It was found that DX-88 delayed contact activator induced coagulation without affecting tissue factor mediated coagulations, and the use of PT or tissue factor-activated TEG may be preferable in comparison with aprotinin. Expand
A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
TLDR
Despite the possibility of a modest reduction in the risk of massive bleeding, the strong and consistent negative mortality trend associated with aprotinin, as compared with the lysine analogues, precludes its use in high-risk cardiac surgery. Expand
DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
TLDR
Observations suggest that direct inhibition of FXa could be preferable to warfarin in the suppression of thrombosis without haemorrhagic complications. Expand
Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: no
TLDR
The position that aprotinin is not a useful first choice hemostatic agent in cardiopulmonary surgery is based on the availability of a class of drugs – the lysine analogs tranexamic acid and epsilon-aminocaproic acid – that are as efficacious as aProtinin and about 4-fold less expensive. Expand
Review and application of serine protease inhibition in coronary artery bypass graft surgery.
  • L. Engles
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2005
TLDR
Aprotinin is the only agent that has an FDA indication to prevent blood loss and transfusion during CABG surgery, and the additional benefit of attenuating the systemic inflammatory response associated with CabG with CPB. Expand
The risk associated with aprotinin in cardiac surgery.
TLDR
The association between aprotinin and serious end-organ damage indicates that continued use is not prudent, and the less expensive generic medications aminocaproic acid and tranexamic acid are safe alternatives. Expand
Crystallization and preliminary X-ray analysis of a Kunitz-type inhibitor, textilinin-1 from Pseudonaja textilis textilis.
TLDR
The crystallization of recombinant textilinin-1 as the free molecule and in complex with bovine trypsin (229 amino acids) is reported and it is expected that the overall fold of these molecules is similar but that they have contrasting surface features. Expand
Inhibition of activated protein C by aprotinin and the use of the insolubilized inhibitor for its purification.
TLDR
It is demonstrated that aprotinin is a potent competitive inhibitor of APC with a Ki of 1.35 mumol/L and that APC could be purified, after activation, in a one-stage procedure out of a mixture of protein such as a prothrombin complex concentrate. Expand
...
1
2
3
...